2025 CSCO指南更新：亚盛医药-B(06855)APG-2575首获推荐耐立克®获升级推荐

智通财经2025-04-21

智通财经APP讯，亚盛医药-B(06855)发布公告，公司自主研发的两款重磅创新药均获纳入2025年中国临床肿瘤学会(CSCO)系列指南：在研品种新型口服 Bcl-2选择性抑制剂Lisaftoclax(APG-2575)首次获《CSCO淋巴瘤诊疗指南》推荐。公司原创1类新药、新一代酪氨酸激酶抑制剂(TKI)奥雷巴替尼片(商品名：耐立克®)获《 CSCO儿童及青少年白血病诊疗指南》升级推荐;延续《...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2529877876?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-21 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529877876","market":"us","top_or_hot":-1,"title":"2025 CSCO指南更新：亚盛医药-B(06855)APG-2575首获推荐 耐立克®获升级推荐","media":"智通财经","content":"<div>\n<p>智通财经APP讯，亚盛医药-B(06855)发布公告，公司自主研发的两款重磅创新药均获纳入2025年中国临床肿瘤学会(CSCO)系列指南：在研品种新型口服 Bcl-2选择性抑制剂Lisaftoclax(APG-2575)首次获《CSCO淋巴瘤诊疗指南》推荐。公司原创1类新药、新一代酪氨酸激酶抑制剂(TKI)奥雷巴替尼片(商品名：耐立克®)获《 CSCO儿童及青少年白血病诊疗指南》升级推荐;延续《...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1281643.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2025 CSCO指南更新：亚盛医药-B(06855)APG-2575首获推荐 耐立克®获升级推荐</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2025 CSCO指南更新：亚盛医药-B(06855)APG-2575首获推荐 耐立克®获升级推荐\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-21 19:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1281643.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，亚盛医药-B(06855)发布公告，公司自主研发的两款重磅创新药均获纳入2025年中国临床肿瘤学会(CSCO)系列指南：在研品种新型口服 Bcl-2选择性抑制剂Lisaftoclax(APG-2575)首次获《CSCO淋巴瘤诊疗指南》推荐。公司原创1类新药、新一代酪氨酸激酶抑制剂(TKI)奥雷巴替尼片(商品名：耐立克®)获《 CSCO儿童及青少年白血病诊疗指南》升级推荐;延续《...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1281643.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1281643.html","article_id":"2529877876","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529877876","pubTimestamp":1745234776,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，亚盛医药-B 发布公告，公司自主研发的两款重磅创新药均获纳入2025年中国临床肿瘤学会系列指南：在研品种新型口服 Bcl-2选择性抑制剂Lisaftoclax首次获《CSCO淋巴瘤诊疗指南》推荐。2024年11月，Lisaftoclax单药治疗R/R CLL/SLL的NDA申请已获国家药监局药品审评中心受理并纳入优先审评。此次2025版《 CSCO儿童及青少年白血病诊疗指南》在针对费城染色体阳性急性淋巴细胞白血病儿童患者的治疗中，首次将奥雷巴替尼升级为I级推荐治疗方案用于BCR-ABL1激酶区T315I突变患者。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4581":"高盛持仓","BK4560":"网络安全概念","LU0731783394.SGD":"Fidelity Global Dividend A-MINCOME(G)-SGD","LU1235294995.USD":"FIDELITY GLOBAL TECHNOLOGY \"A\" (USDHDG) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","BK4527":"明星科技股","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4020":"通信设备","LU2125909916.SGD":"Natixis Thematics Safety R/A SGD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4534":"瑞士信贷持仓","BK1574":"生物医药B类股","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1046421795.USD":"富达环球科技A-ACC","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","AAPG":"亚盛医药","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","CSCO":"思科","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4579":"人工智能","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","06855":"亚盛医药-B","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","BK4550":"红杉资本持仓","LU1599440770.SGD":"FIDELITY GLOBAL DIVIDEND \"A\" (SGDHDG) INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","APG":"APi Group Corp","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4525":"远程办公概念","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC"},"translate_title":"2025 CSCO Guidelines Update: Ascentage Pharma-B (06855) APG-2575 was recommended for the first time, and Nellick ® was upgraded and recommended","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APG":1,"AAPG":1,"06855":1,"CSCO":1},"content_text":"智通财经APP讯，亚盛医药-B(06855)发布公告，公司自主研发的两款重磅创新药均获纳入2025年中国临床肿瘤学会(CSCO)系列指南：在研品种新型口服 Bcl-2选择性抑制剂Lisaftoclax(APG-2575)首次获《CSCO淋巴瘤诊疗指南》推荐。公司原创1类新药、新一代酪氨酸激酶抑制剂(TKI)奥雷巴替尼片(商品名：耐立克®)获《 CSCO儿童及青少年白血病诊疗指南》升级推荐;延续《CSCO恶性血液病诊疗指南》相关推荐。作为全球第二个递交新药上市申请(NDA)的Bcl-2抑制剂、中国首个递交NDA 并进入优先审评的国产原研Bcl-2抑制剂，Lisaftoclax(APG-2575)凭借其优异的临床数据，获2025版《 CSCO淋巴瘤诊疗指南》推荐，用于单药治疗复发╱ 难治性(R/R)慢性淋巴细胞白血病╱小淋巴细胞淋巴瘤(CLL/SLL)患者。这是 Lisaftoclax(APG-2575)首次获纳入CSCO指南，并且是唯一获得指南推荐的中国原研Bcl-2抑制剂，标志着亚盛医药在推动该创新品种真正惠及患者的道路上迈出里程碑式一步，同时标志着中国原研创新药在血液肿瘤领域的重大突破。2024年11月，Lisaftoclax(APG-2575)单药治疗R/R CLL/SLL的NDA申请已获国家药监局药品审评中心(CDE)受理并纳入优先审评。Lisaftoclax(APG-2575) 针对CLL/SLL领域正在全球范围内同步推进两项注册III期临床： Lisaftoclax(APG-2575)联合BTK抑制剂针对BTK抑制剂经治CLL/SLL患者的全球注册III期临床研究(GLORA研究);Lisaftoclax(APG-2575)联合阿可替尼对比免疫化疗治疗针对初治CLL/SLL患者的全球注册III期临床研究(GLORA-2研究)，从而进一步拓展治疗边界。此次2025版《 CSCO儿童及青少年白血病诊疗指南》在针对费城染色体阳性急性淋巴细胞白血病(Ph+ ALL)儿童患者的治疗中，首次将奥雷巴替尼升级为I级推荐治疗方案用于BCR-ABL1激酶区T315I突变患者。这标志着奥雷巴替尼在儿童血液领域开启了全新篇章。同时在2025年《 CSCO恶性血液病诊疗指南》中，奥雷巴替尼在CML治疗领域延续多项重要推荐，巩固了其在CML治疗中的关键地位。在CML-慢性期(CP)治疗中，奥雷巴替尼是任何线T315I突变的I级推荐治疗方案;也是尼洛替尼或达沙替尼一线治疗失败后的二线治疗，以及对≥2种TKI不耐受或╱且治疗失败后的叁线治疗的I级推荐治疗方案。在CML-进展期治疗中，奥雷巴替尼也作为I级推荐治疗方案用于CML-加速期(AP)伴T315I患者，以及从CP进展为AP、从CP 或AP进展为BP患者。该指南还强调了在应对多种BCR::ABL1突变(包括T315I、 V299L、F317L/V/I/C、T315A、Y253H、E255K/V、F359C/V/I等)以及任意其他突变(包括复合突变)时的治疗优势。此外，在Ph+ ALL领域，针对诱导缓解以及R/R患者的治疗中，奥雷巴替尼均延续I级推荐。奥雷巴替尼是亚盛医药原创1类新药，获国家“重大新药创制”专项支持。作为中国首个获批上市的第叁代BCR-ABL抑制剂，目前奥雷巴替尼已获批用于TKI耐药、并伴有T315I突变的CML – CP或CML-AP成年患者的治疗;对一代和二代 TKI耐药和╱或不耐受的CML-CP成年患者的治疗，且获批适应症均已被纳入国家医保药品目录，极高地提升了患者的可及性。奥雷巴替尼在中国的商业化推广由亚盛医药和信达生物制药共同负责。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2529877876","isCrawlerRequest":true}

2025 CSCO指南更新：亚盛医药-B(06855)APG-2575首获推荐 耐立克®获升级推荐

精彩评论

2025 CSCO指南更新：亚盛医药-B(06855)APG-2575首获推荐耐立克®获升级推荐